Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.
Emily Wynja, MSIV
Advertisement
Articles by Emily Wynja, MSIV
Advertisement
Latest Updated Articles
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited TissuePublished: October 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
2
How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?
3
QOL Improvement in Breast Cancer Noted With YES System
4
What is Cevostamab’s Mechanism of Action in Multiple Myeloma?
5
